Skip to main content
. 2020 May 10;395(10238):1695–1704. doi: 10.1016/S0140-6736(20)31042-4

Table 4.

Adverse events in the study population

Combination group (n=86) Control group (n=41) p value
Adverse events
Nausea 30 (35%) 13 (32%) 0·87
Diarrhoea 34 (40%) 18 (44%) 0·54
Increased alanine aminotransferase 11 (13%) 7 (17%) 0·32
Hyperbilirubinaemia 4 (5%) 3 (7%) 0·54
Sinus bradycardia 3 (4%) 1 (2%) 0·77
Fever 32 (37%) 16 (39%) 0·73
Serious adverse events 0 1 (2%) 0·15
Duration of nausea, days 2 (1–2) 2 (1–2) 0·80
Duration of diarrhoea, days 3 (3–3) 3 (3–3) 0·88